The synthetic ERR agonist dubbed "exercise in a pill" after preclinical studies showed 50% longer running endurance and significant fat loss without any training.
SLU-PP-332 is a synthetic pan-agonist of the estrogen-related receptors (ERRα, ERRβ, ERRγ) — a family of orphan nuclear receptors that govern mitochondrial biogenesis, fatty acid oxidation, and oxidative metabolism. It was identified at Saint Louis University as part of a program to find drug-like ERR agonists.
It’s earned the nickname "exercise mimetic" because animal studies show it produces many of the same adaptations as endurance training — without any actual training. In mice, it extended running endurance by ~50% and produced measurable fat loss at unchanged food intake.
Not FDA approved. Preclinical research only (no completed human trials as of 2026). Not WADA prohibited — but check before competition, as metabolic agonists are on WADA’s monitoring list. Available as research chemical only.
Directly activates all three ERR isoforms. These receptors are downstream effectors of PGC-1α (the "master regulator" of mitochondrial biogenesis) — when ERR is active, the cell reads it as "we need more mitochondria."
Increases mitochondrial density and oxidative capacity in skeletal muscle. The same adaptation that endurance training produces — without the training.
Upregulates genes involved in beta-oxidation, causing cells to preferentially burn fat for fuel. Main mechanism for observed fat loss at unchanged intake.
Promotes type I (slow-twitch, oxidative) muscle fiber characteristics — which is why endurance gains are larger than strength gains in animal studies.
SLU-PP-332 is preclinical only — no human trials completed. The animal data is striking enough to drive significant community interest, but translate with appropriate skepticism.
| Benefit | Evidence |
|---|---|
| Endurance | ~50% longer treadmill running time in obese sedentary mice |
| Fat loss | Significant fat reduction at unchanged food intake in diet-induced obesity models |
| Metabolic rate | Increased oxygen consumption and energy expenditure |
| Mitochondrial density | Measurable increase in muscle mitochondrial content |
| Glucose tolerance | Improved insulin sensitivity in animal models |
| Stacks with MOTS-C | Complementary pathway — MOTS-C activates AMPK, SLU-PP-332 activates ERR; theoretical synergy |
Human dosing is not clinically established. Community doses are extrapolated from animal studies — treat results with appropriate caution.
Build your protocol, log every dose, monitor your body's response, and get reminders so you never miss a dose.
Start Tracking FreeHuman dosing is not clinically established. Start low (5 mg/day) and assess tolerance before increasing.
Some suppliers offer injectable SubQ forms at lower doses (1–3 mg/day). Oral is more common for convenience. No published pharmacokinetic data compares oral vs. injectable bioavailability for SLU-PP-332 in humans or animals — the common claim that “injectable offers more consistent bioavailability” is speculative rather than PK-confirmed, so treat route choice as a matter of convenience and per-mg cost, not established delivery superiority.
Usually supplied as oral capsules or powder — no reconstitution required for oral. If supplied as injectable powder, reconstitute with 2 mL BAC water for ~2.5 mg/mL (for a 5 mg vial) and draw 0.4 mL = 40 units per 1 mg dose.
Use our free peptide calculator to figure out your reconstitution volume, draw amount, and syringe units.
Open Peptide CalculatorDosing cheat sheet, reconstitution reference, and cycle planning — delivered to your inbox.
Human safety data is limited. Animal studies show a favorable profile, but translating to human side effects requires caution.
Looking for SLU-PP-332? We recommend NextGen Peptides — third-party tested, fast shipping, and trusted by the StackTrax community.
10% off with code
Exclusive StackTrax discount
Build your protocol, log every dose, monitor your body's response, and get reminders so you never miss a dose.
Start Tracking FreeDisclaimer: This guide is for educational and informational purposes only and is not intended as medical advice, diagnosis, or treatment. The compounds discussed are not FDA approved for human use. Always consult a qualified healthcare provider before starting any new supplement or peptide protocol. StackTrax does not sell peptides or supplements directly — purchase links go to third-party vendors. StackTrax is not responsible for the products, quality, or business practices of any third-party vendor. This page contains affiliate links — StackTrax may earn a commission on purchases at no extra cost to you.
© 2026 StackTrax, LLC. All rights reserved.
StackTrax guides cover peptides and compounds that are not FDA-approved for the uses discussed. The dosing, reconstitution, and safety information is compiled from published research and community protocols for educational purposes only.
Before using any compound mentioned here, consult a qualified healthcare provider. StackTrax does not sell, prescribe, or recommend these substances for personal use.
These pages also contain affiliate links. We may earn a commission on purchases at no extra cost to you — this never changes our editorial recommendations.